Literature DB >> 1002821

Growth hormone and prolactin release in acromegalic patients following metergoline administration.

G Delitala, A Masala, S Alagna, L Devilla, G Lotti.   

Abstract

In six acromegalite patients oral administration of 4 mg of metergoline, an antiserotonin agent, produced a fall in plasma growth hormone (GH) and prolactin (PRL) concentrations. In the same patients this inhibitory effect was observed after administration of dopaminergic drugs, L-Dopa and 2-Br-alpha-ergocryptine. Both GH and PRL levels remained suppressed during a 6 day course of treatmnt with metergoline. These results are consistent with the hypothesis that the inhibitory effect of netergoline on GH and PRL release is determined by inactivation of serotonin receptors in the hypothalamus or at the pituitary.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1002821     DOI: 10.1210/jcem-43-6-1382

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

Review 1.  gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness.

Authors:  Daniel Pardi; Jed Black
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  Metergoline and cyproheptadine suppress prolactin release by a non-5-hydroxytryptaminergic, non-dopaminergic mechanism.

Authors:  G M Besser; G Delitala; A Grossman; T Yeo
Journal:  Br J Pharmacol       Date:  1980-09       Impact factor: 8.739

Review 3.  Recent developments in acromegaly: a review.

Authors:  A Jadresic
Journal:  J R Soc Med       Date:  1983-11       Impact factor: 18.000

4.  Recurrent acromegaly associated with completely empty sella and otherwise normal pituitary function.

Authors:  S Ng Tang Fui; R Cerio; H Keen; O Shaheen
Journal:  J R Soc Med       Date:  1983-11       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.